Investigational HIV vaccine regimen shows encouraging results in non-human primates

July 2, 2015, Johnson & Johnson
Diagrammatical representation of the molecular structure of HIV-1 protease complexed with the inhibitor indinavir. Credit: Public Domain

Johnson & Johnson announced today that scientists at Beth Israel Deaconess Medical Center (BIDMC), Crucell Holland B.V, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and several other collaborators today published results from a preclinical study of an HIV vaccine regimen used in in non-human primates. The study, published in the online edition of Science, suggests that a "heterologous prime-boost" vaccine regimen—which first primes the immune system, then boosts the immune system to increase the response, could ultimately prove to be a strategy for protecting against global human immunodeficiency virus (HIV-1) infection.

These data form the basis of regimens that are now being evaluated in an international phase 1/2a clinical trial for safety and immunogenicity in healthy, HIV-uninfected volunteers.

"Despite great progress in HIV treatments, HIV remains one of the greatest global health threats of our time with millions continuing to be infected each year. Our ultimate goal is to develop a vaccine that prevents HIV in the first place. By Janssen collaborating with multiple stakeholders on new tools, we hope one day to help eradicate HIV," said Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson.

The pre-clinical study published today evaluated the protective efficacy of a "prime-boost" vaccine approach, which leverages AdVac Technology from Janssen and a trimeric envelope protein boost. Non-human primates (NHP) were first given an adenovirus serotype 26 (Ad26) vectored vaccine to prime the , and then a boost of a purified HIV envelope protein intended to enhance the immune system over time. This approach is intended to increase both the magnitude of the immune response and the overall protection against subsequent viral challenge. A heterologous prime-boost vaccine regimen using a similar AdVac vector, along with an MVA-based vector, is being used in Janssen's preventative Ebola candidate vaccine regimen that is currently in Phase 1 human clinical studies.

Pre-Clinical Results Lead to Human Study

The study results show that the investigational prime-boost vaccine regimen provided complete protection from becoming infected with simian immunodeficiency virus (SIV), a virus similar to HIV that infects NHPs, in half of the vaccinated NHPs (n=12) against a series of six repeated challenges. This work also demonstrates that there is a strong link between the protective ability of the vaccine regimen and the number of antibody functions to fight the virus, so called polyfunctionality, which supports the continued development of the vaccine regimen for human use. These results have previously been presented at several international congresses.

"We are very encouraged by the results of this preclinical HIV vaccine study, and the findings lead to a clear path forward for evaluating this HIV vaccine candidate in humans," said lead author Dan H. Barouch, MD, PhD, Director of the Center for Virology and Vaccine Research at BIDMC and Professor of Medicine at Harvard Medical School.

The phase 1/2a study (HIV-V-A004) is currently enrolling 400 volunteers in the United States and Rwanda to evaluate heterologous prime-boost regimens, with sites in South Africa, Uganda and Thailand opening soon. Ongoing phase 1 clinical studies have been evaluating the safety and immunogenicity of different components which are included in the regimens to be used in this study.

The HIV-1 and Ebola AdVac-based vaccine regimens, along with Janssen's investigational candidate inactivated polio vaccine, utilize Janssen's PER.C6 production cell line technology which has the potential to reduce costs by increasing vaccine production at lower volumes, to develop, manufacture and, upon approval, commercialize vaccines.

Explore further: Clinical trial evaluates heterologous prime/boost regimens in preventative HIV vaccination

More information: Protective efficacy of adenovirus-protein vaccines against SIV challenges in rhesus monkeys, Science, … 1126/science.aab3886

Related Stories

Clinical trial evaluates heterologous prime/boost regimens in preventative HIV vaccination

October 1, 2014
Almost 40 million people worldwide live with HIV/AIDS, with an estimated 2.5 million new cases per year. Therefore, there has been a large global effort to develop an effective vaccine against the virus. HIV-1 vaccine development ...

Oxford Vaccine Group begins first trial of new Ebola vaccine

January 6, 2015
Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).

Experimental vaccine partially protects monkeys from HIV-like infection

January 4, 2012
Results from a recent study show that novel vaccine combinations can provide partial protection against infection by Simian Immunodeficiency Virus (SIV) in rhesus monkeys. In addition, in the animals that became infected, ...

Past HIV vaccine trials reveal new path to success

March 19, 2014
A multi-national research team led by Duke Medicine scientists has identified a subclass of antibodies associated with an effective immune response to an HIV vaccine.

Researchers design global HIV vaccine that shows promise in monkeys

October 24, 2013
The considerable diversity of HIV worldwide represents a critical challenge for designing an effective HIV vaccine. Now, a scientific team led by Beth Israel Deaconess Medical Center (BIDMC) has shown that bioinformatically ...

Antibody response linked to lower mother-to-child HIV transmission

June 8, 2015
How most babies are protected from acquiring HIV from their infected mothers has been a matter of scientific controversy. Now researchers at Duke Medicine provide new data identifying an antibody response that had long been ...

Recommended for you

HIV vaccine protects non-human primates from infection

December 14, 2018
For more than 20 years, scientists at Scripps Research have chipped away at the challenges of designing an HIV vaccine. Now new research, published in Immunity, shows that their experimental vaccine strategy works in non-human ...

Roadmap reveals shortcut to recreate key HIV antibody for vaccines

December 11, 2018
HIV evades the body's immune defenses through a multitude of mutations, and antibodies produced by the host's immune system to fight HIV also follow convoluted evolutionary pathways that have been challenging to track.

Eliminating the latent reservoir of HIV

December 7, 2018
A new study suggests that a genetic switch that causes latent HIV inside cells to begin to replicate can be manipulated to completely eradicate the virus from the human body. Cells harboring latent HIV are "invisible" to ...

New research highlights why HIV-infected patients suffer higher rates of cancer

December 5, 2018
AIDS patients suffer higher rates of cancer because they have fewer T-cells in their bodies to fight disease. But new research examines why HIV-infected patients have higher rates of cancer—among the leading causes of death ...

Focus on resistance to HIV offers insight into how to fight the virus

November 30, 2018
Of the 40 million people around the world infected with HIV, less than one per cent have immune systems strong enough to suppress the virus for extended periods of time. These special immune systems are known as "elite controllers." ...

Patients with rare natural ability to suppress HIV shed light on potential functional cure

November 27, 2018
Researchers at Johns Hopkins have identified two patients with HIV whose immune cells behave differently than others with the virus and actually appear to help control viral load even years after infection. Moreover, both ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jul 02, 2015
Use this in shortage of victims/'volunteers'. They'll be just dyin' ta' get in.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.